Molecular Cancer

Article	Citations
The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments	1263
Metabolically activated and highly polyfunctional intratumoral VISTA+ regulatory B cells are associated with tumor recurrence in early-stage NSCLC	770
Retraction Note: Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway	725
Retraction Note: Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression	666
Retraction Note: Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer	528
Retraction Note to: Linc00210 drives Wnt/β-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner	489
Editorial expression of concern: Activation of the NF-κB pathway as a mechanism of alcohol enhanced progression and metastasis of human hepatocellular carcinoma	471
Retraction Note: CircTLK1 promotes the proliferation and metastasis of renal cell carcinoma by sponging miR-136-5p	452
Retraction Note: α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway	447
Engineered multifunctional nanoparticles for enhanced radiation therapy: three-in-one approach for cancer treatment	432
Contract to kill: GNAS mutation	418
Bridging epigenomics and tumor immunometabolism: molecular mechanisms and therapeutic implications	385
Minimally invasive approaches for the early detection of endometrial cancer	362
Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome	341
The double agents in liquid biopsy: promoter and informant biomarkers of early metastases in breast cancer	310
Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer	272
Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy	252
CircIL4R activates the PI3K/AKT signaling pathway via the miR-761/TRIM29/PHLPP1 axis and promotes proliferation and metastasis in colorectal cancer	249
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges	243
Unleashing T cell anti-tumor immunity: new potential for 5-Nonloxytryptamine as an agent mediating MHC-I upregulation in tumors	242
Radioresistance in rectal cancer: can nanoparticles turn the tide?	240
Retraction Note to: LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis	240
Ferroptosis and pyroptosis are connected through autophagy: a new perspective of overcoming drug resistance	234
Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells	233
Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes	219

The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research	216
PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation	201
Targeting m7G-enriched circKDM1A prevents colorectal cancer progression	195
LINC01852 inhibits the tumorigenesis and chemoresistance in colorectal cancer by suppressing SRSF5-mediated alternative splicing of PKM	185
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression	181
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial	176
Single cell RNA-seq analysis identifies a noncoding RNA mediating resistance to sorafenib treatment in HCC	168
Extracellular vesicles in tumor immunity: mechanisms and novel insights	165
N6-methyladenosine-modified SENP1, identified by IGF2BP3, is a novel molecular marker in acute myeloid leukemia and aggravates progression by activating AKT signal via de-SUMOylating HDAC2	161
Incidence, risk factors, and epidemiological trends of tracheal cancer: a global analysis	159
Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing	156
Correction: The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin	155
Understanding gold nanoparticles and their attributes in ovarian cancer therapy	153
DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer	152
Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial	147
SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis	146
Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery	142
Tumor buster - where will the CAR-T cell therapy ‘missile’ go?	142
Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies	140
Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma	138
Clustering cancers by shared transcriptional risk reveals novel targets for cancer therapy	137
The circSPON2/miR-331-3p axis regulates PRMT5, an epigenetic regulator of CAMK2N1 transcription and prostate cancer progression	131
E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer	131
i-CRISPR: a personalized cancer therapy strategy through cutting cancer-specific mutations	130
Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia	130
Unraveling the key role of chromatin structure in cancer development through epigenetic landscape characterization of oral cancer	127
Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy	126
LAMTOR1 decreased exosomal PD-L1 to enhance immunotherapy efficacy in non-small cell lung cancer	125
Exploiting autophagy balance in T and NK cells as a new strategy to implement adoptive cell therapies	125
Multi-omics and clustering analyses reveal the mechanisms underlying unmet needs for patients with lung adenocarcinoma and identify potential therapeutic targets	124
Novel humanized monoclonal antibodies against ROR1 for cancer therapy	123
A multidimensional recommendation framework for identifying biological targets to aid the diagnosis and treatment of liver metastasis in patients with colorectal cancer	121
Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells	121
A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology	119
Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma	118
The miR-23a/27a/24 − 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer	115
A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer	113
Crosstalk of pyroptosis and cytokine in the tumor microenvironment: from mechanisms to clinical implication	113
Pals1 prevents Rac1-dependent colorectal cancer cell metastasis by inhibiting Arf6	111
An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma	111
Crosstalk between N6-methyladenosine modification and circular RNAs: current understanding and future directions	110
A novel polypeptide CAPG-171aa encoded by circCAPG plays a critical role in triple-negative breast cancer	106
Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial	105
Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives	105
Correction: Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma	104
Correction: A novel approach for relapsed/refractory FLT3mut+acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib	103
Correction to: Long non-coding RNA UCA1 promotes malignant phenotypes of renal cancer cells by modulating the miR-182-5p/DLL4 axis as a ceRNA	102
Correction: Nac1 promotes stemness and regulates myeloid‑derived cell status in triple‑negative breast cancer	102
Correction to: LMTK3 inhibition affects microtubule Stability	102
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy	102

Correction: m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC	101
Correction to: Circular RNA circERBB2 promotes gallbladder cancer progression by regulating PA2G4-dependent rDNA transcription	100
Co-occurring mutations identify prognostic subgroups of microsatellite stable colorectal cancer	98
Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance	98
Correction to: The function and mechanisms of action of circular RNAs in Urologic Cancer	95
Correction: Reprogramming anchorage dependency by adherent‑to‑suspension transition promotes metastatic dissemination	95
Proteogenomic characterization of molecular and cellular targets for treatment-resistant subtypes in locally advanced cervical cancers	95
The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC	94
A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy	92
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers	91
NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancer	91
Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application	90
Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer	90
PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma	89
Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold	88
Extracellular vesicles remodel tumor environment for cancer immunotherapy	88
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway	88
ERK mediates interferon gamma-induced melanoma cell death	88
Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies	86
Chaperone-mediated autophagy modulates Snail protein stability: implications for breast cancer metastasis	86
Mapping cancer biology in space: applications and perspectives on spatial omics for oncology	86
DNMT1-targeting remodeling global DNA hypomethylation for enhanced tumor suppression and circumvented toxicity in oral squamous cell carcinoma	85
Metal-enriched HSP90 nanoinhibitor overcomes heat resistance in hyperthermic intraperitoneal chemotherapy used for peritoneal metastases	85
Essential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers	85
TGF-β signaling promotes cervical cancer metastasis via CDR1as	85
Genome editing via non-viral delivery platforms: current progress in personalized cancer therapy	85
Immunotherapies in rare cancers	84
Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance	84
Using single-cell sequencing technology to detect circulating tumor cells in solid tumors	83
Circular RNA circDCUN1D4 suppresses hepatocellular carcinoma development via targeting the miR-590-5p/ TIMP3 axis	82
SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities	82
Two circPPFIA1s negatively regulate liver metastasis of colon cancer via miR-155-5p/CDX1 and HuR/RAB36	82
Evolution of cell therapy for renal cell carcinoma	81
Correction: CircZBTB44 promotes renal carcinoma progression by stabilizing HK3 mRNA structure	79
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial	78
Immunotherapy: an emerging modality to checkmate brain metastasis	78
LINC00922 decoys SIRT3 to facilitate the metastasis of colorectal cancer through up-regulation the H3K27 crotonylation of ETS1 promoter	78
Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo	77
Long noncoding RNA DLGAP1-AS2 promotes tumorigenesis and metastasis by regulating the Trim21/ELOA/LHPP axis in colorectal cancer	76
LINC02159 promotes non-small cell lung cancer progression via ALYREF/YAP1 signaling	76
Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine	76
Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells	76
Correction: Circ-HuR suppresses HuR expression and gastric cancer progression by inhibiting CNBP transactivation	76
A novel NF-κB regulator encoded by circPLCE1 inhibits colorectal carcinoma progression by promoting RPS3 ubiquitin-dependent degradation	76
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy	75
Aberrant R-loop–mediated immune evasion, cellular communication, and metabolic reprogramming affect cancer progression: a single-cell analysis	75
Targeting E2 ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitor suppresses pancreatic cancer growth and metastasis	75
Crosstalk between autophagy inhibitors and endosome-related secretory pathways: a challenge for autophagy-based treatment of solid cancers	75
LINE-1 promotes tumorigenicity and exacerbates tumor progression via stimulating metabolism reprogramming in non-small cell lung cancer	74
The DNA damage sensor ATM kinase interacts with the p53 mRNA and guides the DNA damage response pathway	73
Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program	73
Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p	73
Significant CircRNAs in liver cancer stem cell exosomes: mediator of malignant propagation in liver cancer?	72
CircPIAS1 promotes hepatocellular carcinoma progression by inhibiting ferroptosis via the miR-455-3p/NUPR1/FTH1 axis	71
Lung cancer immunotherapy: progress, pitfalls, and promises	71
m6A-regulated tumor glycolysis: new advances in epigenetics and metabolism	71
Therapeutic challenges in peripheral T-cell lymphoma	71
Circulating cell-free DNA methylation patterns as non-invasive biomarkers to monitor colorectal cancer treatment efficacy without referencing primary site mutation profiles	71
CircRNF220, not its linear cognate gene RNF220, regulates cell growth and is associated with relapse in pediatric acute myeloid leukemia	69
New frontiers in immune checkpoint B7-H3 (CD276) research and drug development	69
m6A modification: recent advances, anticancer targeted drug discovery and beyond	69
Hijacking of the nervous system in cancer: mechanism and therapeutic targets	69
Neutrophils in Cancer immunotherapy: friends or foes?	69
Cancer cell-derived exosomal circUSP7 induces CD8+ T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC	68
NK cells and solid tumors: therapeutic potential and persisting obstacles	68
Remodeling of the tumor microenvironment via disrupting Blimp1+ effector Treg activity augments response to anti-PD-1 blockade	67
Circular RNAs in tumor immunity and immunotherapy	67
EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3	67
The FUS/circEZH2/KLF5/ feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition	67
Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy	66
Exosomal circSIPA1L3-mediated intercellular communication contributes to glucose metabolic reprogramming and progression of triple negative breast cancer	66
lncRNA ZNRD1-AS1 promotes malignant lung cell proliferation, migration, and angiogenesis via the miR-942/TNS1 axis and is positively regulated by the m6A reader YTHDC2	66
The senescence journey in cancer immunoediting	65
The roles of tumor-derived exosomes in altered differentiation, maturation and function of dendritic cells	65
hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma	64
Drug resistance in ovarian cancer: from mechanism to clinical trial	64
Nanomedicines harnessing cGAS-STING pathway: sparking immune revitalization to transform ‘cold’ tumors into ‘hot’ tumors	64
Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes	63
Exosomal circLPAR1 functions in colorectal cancer diagnosis and tumorigenesis through suppressing BRD4 via METTL3–eIF3h interaction	63
Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer	63

Histone citrullination: a new target for tumors	63
The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis	62
CircRNF13 enhances IGF2BP1 phase separation-mediated ITGB1 mRNA stabilization in an m6A-dependent manner to promote oral cancer cisplatin chemoresistance	62
Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy	61
Clinical application and detection techniques of liquid biopsy in gastric cancer	61
Cancer, metastasis, and the epigenome	61
A novel protein encoded by circMAPK1 inhibits progression of gastric cancer by suppressing activation of MAPK signaling	60
A novel protein AXIN1-295aa encoded by circAXIN1 activates the Wnt/β-catenin signaling pathway to promote gastric cancer progression	60
CircPCNXL2 promotes tumor growth and metastasis by interacting with STRAP to regulate ERK signaling in intrahepatic cholangiocarcinoma	59
CircMYH9 drives colorectal cancer growth by regulating serine metabolism and redox homeostasis in a p53-dependent manner	59
Expression of mTOR in normal and pathological conditions	59
The epigenetic regulatory mechanism of PIWI/piRNAs in human cancers	59
The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p	58
The use of RNA-based treatments in the field of cancer immunotherapy	58
Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment	58
Cancer therapy resistance mediated by cancer-associated fibroblast-derived extracellular vesicles: biological mechanisms to clinical significance and implications	58
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer	57
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T	57
CRISPR based therapeutics: a new paradigm in cancer precision medicine	57
METTL14-mediated m6A modification of circORC5 suppresses gastric cancer progression by regulating miR-30c-2-3p/AKT1S1 axis	57
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer	57
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy	56
circNOX4 activates an inflammatory fibroblast niche to promote tumor growth and metastasis in NSCLC via FAP/IL-6 axis	55
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer	55
Cuproptosis: mechanisms and links with cancers	55
The function and mechanisms of action of circular RNAs in Urologic Cancer	55
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells	55
Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches	55
The University of Kansas Cancer Center (KUCC), an NCI designated comprehensive cancer center	54
o8G-modified circPLCE1 inhibits lung cancer progression via chaperone-mediated autophagy	54
Nanotechnology-leveraged CRISPR/Cas systems: icebreaking in trace cancer-related nucleic acids biosensing	54
Expanding uncapped translation and emerging function of circular RNA in carcinomas and noncarcinomas	53
circRNAs shed light on cancer diagnosis and treatment	53
Lactate accumulation induces H4K12la to activate super-enhancer-driven RAD23A expression and promote niraparib resistance in ovarian cancer	53
Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma	53
A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer	53
The epigenetic hallmarks of immune cells in cancer	52
CXCR2 expression during melanoma tumorigenesis controls transcriptional programs that facilitate tumor growth	52
Correction: CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-IRNA-editing	50
Bidirectional role of neutrophils in tumor development	50
Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment	50
Correction to: The lncRNA UCA1 promotes proliferation, migration, immune escape and inhibits apoptosis in gastric cancer by sponging anti-tumor miRNAs	50
Extracellular vesicles in cancer´s communication: messages we can read and how to answer	49
Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection	49
Mechanisms and cross-talk of regulated cell death and their epigenetic modifications in tumor progression	48
Deciphering the role of LGALS2: insights into tertiary lymphoid structure-associated dendritic cell activation and immunotherapeutic potential in breast cancer patients	48
The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1	48
Myofibroblast-derived extracellular vesicles facilitate cancer stemness of hepatocellular carcinoma via transferring ITGA5 to tumor cells	48
Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies	48
Correction: CircPTK2 (hsa_circ_0005273) as a novel therapeutic target for metastatic colorectal cancer	47
Letter to the Editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma	47
Correction: RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy	47
Tumor cell-intrinsic MELK enhanced CCL2-dependent immunosuppression to exacerbate hepatocarcinogenesis and confer resistance of HCC to radiotherapy	47
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer	47
Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity	46
Small cells – big issues: biological implications and preclinical advancements in small cell lung cancer	46
Retraction Note: Loss of vinculin and membrane-bound β-catenin promotes metastasis and predicts poor prognosis in colorectal cancer	46
Resistance mechanisms to immune checkpoint inhibitors: updated insights	46
m6A target microRNAs in serum for cancer detection	46
Circular RNA circBNC2 inhibits tumorigenesis by modulating ferroptosis and acts as a nanotherapeutic target in prostate cancer	45
Mir-483-5p-mediated activating of IGF2/H19 enhancer up-regulates IGF2/H19 expression via chromatin loops to promote the malignant progression of hepatocellular carcinoma	45
The mycobiome in human cancer: analytical challenges, molecular mechanisms, and therapeutic implications	45
Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer	44
Multicancer screening test based on the detection of circulating non haematological proliferating atypical cells	44
CircTTC13 promotes sorafenib resistance in hepatocellular carcinoma through the inhibition of ferroptosis by targeting the miR-513a-5p/SLC7A11 axis	43
Editorial expression of concern: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer	43
Serum small RNAs in metastatic colorectal cancer predict response to chemotherapy and characterize high-risk patients	43
The role of m6A methylation in therapy resistance in cancer	42
Hypoxia and HIFs in Ewing sarcoma: new perspectives on a multi-facetted relationship	42
Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment	42
The m6A RNA methylation regulates oncogenic signaling pathways driving cell malignant transformation and carcinogenesis	42
Targeting the tumor stroma for cancer therapy	41
Insights into N6-methyladenosine and programmed cell death in cancer	40
ESRP1-mediated biogenesis of circPTPN12 inhibits hepatocellular carcinoma progression by PDLIM2/ NF-κB pathway	40
Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine	40
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes	40
The evolution and heterogeneity of neutrophils in cancers: origins, subsets, functions, orchestrations and clinical applications	39
circPTEN1, a circular RNA generated from PTEN, suppresses cancer progression through inhibition of TGF-β/Smad signaling	39
Correction: CircPTPRA blocks the recognition of RNA N6-methyladenosine through interacting with IGF2BP1 to suppress bladder cancer progression	39
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer	39
LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling	38
Correction: lncRNA-PLACT1 sustains activation of NF-κB pathway through a positive feedback loop with IκBα/E2F1 axis in pancreatic cancer	38
Correction: Coronin 3 promotes gastric cancer metastasis via the up-regulation of MMP-9 and cathepsin K	38
circASAP1 induces renal clear cell carcinoma ferroptosis by binding to HNRNPC and thereby regulating GPX4	38
Correction: circCYP24A1 facilitates esophageal squamous cell carcinoma progression through binding PKM2 to regulate NF-κB-induced CCL5 secretion	38
Correction: A novel tumor suppressor protein encoded by circular AKT3 RNA inhibits glioblastoma tumorigenicity by competing with active phosphoinositide-dependent Kinase-1	38
circ_PPAPDC1A promotes Osimertinib resistance by sponging the miR-30a-3p/ IGF1R pathway in non-small cell lung cancer (NSCLC)	38
Correction: Long non-coding RNA PVT1 promotes tumor progression by regulating the miR-143/HK2 axis in gallbladder cancer	38
Correction: Comprehensive review of CRISPR‑based gene editing: mechanisms, challenges, and applications in cancer therapy	38